{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:13:20Z","timestamp":1773083600897,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.vaccine.2009.01.128","type":"journal-article","created":{"date-parts":[[2009,2,7]],"date-time":"2009-02-07T10:52:28Z","timestamp":1234003948000},"page":"2128-2137","source":"Crossref","is-referenced-by-count":23,"title":["Rabies DNA vaccine: No impact of MHC Class I and Class II targeting sequences on immune response and protection against lethal challenge"],"prefix":"10.1016","volume":"27","author":[{"given":"Manpreet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anant","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2009.01.128_bib1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(02)00287-6","article-title":"Rabies re-examined","volume":"2","author":"Rupprecht","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2009.01.128_bib2","unstructured":"World survey of rabies: No. 32 for the year 1996. Geneva, World Health Organization; 1998 (WHO\/EMC\/ZDI\/98.4)."},{"key":"10.1016\/j.vaccine.2009.01.128_bib3","first-page":"82","article-title":"Rabies: a new look at an old disease","volume":"40","author":"Smith","year":"1993","journal-title":"Prog Med Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2009.01.128_bib4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1096\/fasebj.11.10.9271360","article-title":"Genetic immunization: a new era in vaccines and immunotherapy","volume":"11","author":"Chattergoon","year":"1997","journal-title":"FASEB J"},{"key":"10.1016\/j.vaccine.2009.01.128_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1146\/annurev.immunol.15.1.617","article-title":"DNA vaccine","volume":"15","author":"Donnely","year":"1997","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2009.01.128_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1086\/515613","article-title":"First human trial of a DNA based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host responses","volume":"178","author":"MacGregor","year":"1998","journal-title":"J Infect Dis"},{"issue":"9112","key":"10.1016\/j.vaccine.2009.01.128_bib7","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(97)09440-3","article-title":"Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients","volume":"351","author":"Calarota","year":"1998","journal-title":"Lancet"},{"issue":"5388","key":"10.1016\/j.vaccine.2009.01.128_bib8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.282.5388.476","article-title":"Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine","volume":"282","author":"Wang","year":"1998","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.vaccine.2009.01.128_bib9","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1089\/aid.2006.22.678","article-title":"Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2\/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults","volume":"22","author":"Mulligan","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"10.1016\/j.vaccine.2009.01.128_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.vaccine.2005.08.041","article-title":"Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers","volume":"24","author":"Ceberea","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2009.01.128_bib11","first-page":"1","article-title":"Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine","volume":"4","author":"Margalith","year":"2006","journal-title":"Genet Vaccines Ther"},{"issue":"11","key":"10.1016\/j.vaccine.2009.01.128_bib12","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0264-410X(99)00352-7","article-title":"DNA vaccination of mice against rabies virus: effects of the route of administration and the adjuvant monophosphoryl lipid A (MPLR)","volume":"18","author":"Lodmell","year":"2000","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2009.01.128_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0264-410X(97)88325-9","article-title":"Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection","volume":"16","author":"Lodmell","year":"1998","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2009.01.128_bib14","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1016\/S0264-410X(00)00005-0","article-title":"Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines","volume":"18","author":"Lodmell","year":"2000","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.vaccine.2009.01.128_bib15","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0264-410X(02)00143-3","article-title":"Rabies DNA vaccination of non-human primates: post-exposure studies using gene gun methodology that accelerates induction of neutralizing antibody and enhances neutralizing antibody titers","volume":"20","author":"Lodmell","year":"2002","journal-title":"Vaccine"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2009.01.128_bib16","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0264-410X(98)00328-4","article-title":"Immunization of dogs and cats with a DNA vaccine against rabies virus","volume":"17","author":"Osorio","year":"1999","journal-title":"Vaccine"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2009.01.128_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0264-410X(99)00247-9","article-title":"Immunization of dogs with a DNA vaccine induces protection against rabies virus","volume":"18","author":"Perrin","year":"1999","journal-title":"Vaccine"},{"issue":"17\u201319","key":"10.1016\/j.vaccine.2009.01.128_bib18","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/S0264-410X(00)00475-8","article-title":"Post-exposure DNA vaccination protects mice against rabies virus","volume":"19","author":"Lodmell","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.01.128_bib19","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1016\/S0264-410X(03)00297-4","article-title":"Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody","volume":"21","author":"Lodmell","year":"2003","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2009.01.128_bib20","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.vaccine.2005.09.016","article-title":"Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions","volume":"24","author":"Bahloul","year":"2006","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2009.01.128_bib21","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1016\/S0264-410X(03)00504-8","article-title":"Rabies DNA vaccine in the horse: strategies to improve serological responses","volume":"21","author":"Fischer","year":"2003","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2009.01.128_bib22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0264-410X(03)00568-1","article-title":"Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine","volume":"22","author":"Bahloul","year":"2003","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2009.01.128_bib23","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1128\/IAI.67.9.4780-4786.1999","article-title":"Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences","volume":"67","author":"Li","year":"1999","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2009.01.128_bib24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2567.2004.01823.x","article-title":"DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response","volume":"112","author":"Arruda","year":"2004","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.vaccine.2009.01.128_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/viro.2000.0209","article-title":"Enhancing DNA immunization","volume":"268","author":"Rodriguez","year":"2000","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.vaccine.2009.01.128_bib26","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1128\/IAI.68.6.3097-3102.2000","article-title":"DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity","volume":"68","author":"Delogu","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.01.128_bib27","first-page":"207","article-title":"Development of rabies DNA vaccine using a recombinant plasmid","volume":"49","author":"Rai","year":"2005","journal-title":"Acta Virol"},{"key":"10.1016\/j.vaccine.2009.01.128_bib28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1042\/bj1250697","article-title":"Cortisone-evoked decrease of acid-galactosidase, glucuronidase, N-acetyl-glucosaminidase and arylsulphatase in the ileum of suckling rats","volume":"125","author":"Koldovsk\u00fd","year":"1971","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.vaccine.2009.01.128_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mimet.2006.05.016","article-title":"Breaking down the wall: fractionation of mycobacteria","volume":"68","author":"Rezwan","year":"2007","journal-title":"J Microbiol Methods"},{"issue":"2","key":"10.1016\/j.vaccine.2009.01.128_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.virusres.2005.05.002","article-title":"DNA vaccine for rabies: relevance of the trans-membrane domain of the glycoprotein in generating an antibody response","volume":"113","author":"Rath","year":"2005","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2009.01.128_bib31","series-title":"Laboratory techniques in rabies","first-page":"181","article-title":"A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody","author":"Smith","year":"1996"},{"issue":"3","key":"10.1016\/j.vaccine.2009.01.128_bib32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1128\/IAI.16.3.754-759.1977","article-title":"Rabies virus glycoprotein. II. Biological and serological characterization","volume":"16","author":"Cox","year":"1977","journal-title":"Infect Immun"},{"issue":"20","key":"10.1016\/j.vaccine.2009.01.128_bib33","doi-asserted-by":"crossref","first-page":"7947","DOI":"10.1073\/pnas.83.20.7947","article-title":"Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine","volume":"83","author":"Rupprecht","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"issue":"29","key":"10.1016\/j.vaccine.2009.01.128_bib34","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1016\/j.vaccine.2007.05.024","article-title":"Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies","volume":"25","author":"Hua","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2009.01.128_bib35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.virol.2005.11.042","article-title":"SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens","volume":"347","author":"Gupta","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2009.01.128_bib36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.virol.2006.08.052","article-title":"DNA vaccines against dengue virus based on the ns1 gene: The influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice","volume":"358","author":"Costa","year":"2007","journal-title":"Virology"},{"issue":"27\u201328","key":"10.1016\/j.vaccine.2009.01.128_bib37","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1016\/j.vaccine.2008.04.017","article-title":"Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies","volume":"26","author":"Golden","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.01.128_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2008.08.011","article-title":"Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice","author":"Luo","year":"2008","journal-title":"J Virol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2009.01.128_bib39","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.micinf.2008.02.012","article-title":"Evaluation of the anti-tuberculosis activity generated by different multigene DNA vaccine constructs","volume":"10","author":"Sali","year":"2008","journal-title":"Microbes Infect"},{"issue":"13","key":"10.1016\/j.vaccine.2009.01.128_bib40","doi-asserted-by":"crossref","first-page":"8671","DOI":"10.1074\/jbc.272.13.8671","article-title":"The enhanced immune response to the HIV gp160\/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway","volume":"272","author":"Ruff","year":"1997","journal-title":"J Biol Chem"},{"issue":"39","key":"10.1016\/j.vaccine.2009.01.128_bib41","doi-asserted-by":"crossref","first-page":"37926","DOI":"10.1074\/jbc.M303336200","article-title":"HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility Class II compartment, and elicits enhanced immune responses","volume":"278","author":"Marques","year":"2003","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.vaccine.2009.01.128_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0167-5699(97)84666-X","article-title":"Regulating protein degradation by ubiquitination","volume":"18","author":"Weissman","year":"1997","journal-title":"Immunol Today"},{"issue":"9","key":"10.1016\/j.vaccine.2009.01.128_bib43","first-page":"1965","article-title":"DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors","volume":"58","author":"Chen","year":"1998","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.vaccine.2009.01.128_bib44","doi-asserted-by":"crossref","first-page":"11628","DOI":"10.1128\/JVI.01065-06","article-title":"Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines","volume":"80","author":"Wang","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.01.128_bib45","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1099\/0022-1317-73-2-335","article-title":"Comparison of rabies virus G proteins produced by cDNA-transfected animal cells that display either inducible or constitutive expression of the gene","volume":"73","author":"Morimoto","year":"1992","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.01.128_bib46","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1006\/viro.1995.1289","article-title":"Immune responses to nucleic acid vaccines to rabies virus","volume":"209","author":"Xiang","year":"1995","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.vaccine.2009.01.128_bib47","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1172\/JCI114260","article-title":"Use of mouse anti-rabies monoclonal antibodies in post-exposure treatment of rabies antibodies I post exposure treatment of rabies","volume":"84","author":"Schumacher","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2009.01.128_bib48","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.4049\/jimmunol.163.9.4721","article-title":"In vivo priming by DNA injection occurs predominantly by antigen transfer","volume":"163","author":"Corr","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.01.128_bib49","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1074-7613(00)80255-1","article-title":"MHC-I class restricted CTL responses to exogenous antigens","volume":"5","author":"Jondal","year":"1996","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.vaccine.2009.01.128_bib50","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF03401683","article-title":"Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes","volume":"3","author":"Fu","year":"1997","journal-title":"Mol Med"},{"key":"10.1016\/j.vaccine.2009.01.128_bib51","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","article-title":"DNA vaccines: immunology, application, and optimization","volume":"18","author":"Gurunathan","year":"2000","journal-title":"Annu Rev Immunol"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2009.01.128_bib52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0161-5890(02)00105-0","article-title":"Alternative processing of endogenous or exogenous antigens extends the immunogenic, H-2 class-I restricted peptide repertoire","volume":"39","author":"Schirmbeck","year":"2002","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2009.01.128_bib53","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.15.1.821","article-title":"Capture and processing of exogenous antigens for presentation on MHC molecules","volume":"15","author":"Watts","year":"1997","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2009.01.128_bib54","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/1521-4141(2000)30:8<2333::AID-IMMU2333>3.0.CO;2-F","article-title":"Characterization of MHC class II-presented peptides generated from an antigen targeted to different endocytic compartments","volume":"30","author":"Fernandes","year":"2000","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2009.01.128_bib55","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1084\/jem.191.11.1957","article-title":"Receptor-mediated uptake of antigen\/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways","volume":"191","author":"Castellino","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2009.01.128_bib56","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.4049\/jimmunol.166.7.4355","article-title":"Multiple antigen-specific processing pathways for activating naive CD8+ T cells in vivo","volume":"166","author":"Norbury","year":"2001","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2009.01.128_bib57","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11373-005-9012-3","article-title":"Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies","volume":"12","author":"Peng","year":"2005","journal-title":"J Biomed Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2009.01.128_bib58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.imlet.2007.05.007","article-title":"Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines","volume":"111","author":"Doba\u00f1o","year":"2007","journal-title":"Immunol Lett"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0900200X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0900200X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T22:27:31Z","timestamp":1684880851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X0900200X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":58,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0264410X0900200X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.01.128","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}